Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gallic acid carbon dots
- Development stage
- Preclinical
- Lead developer
- Huazhong University of Science and Technology
- Modality
- Nanoparticles → Drug Delivery Systems
01
Overview
Gallic acid carbon dots (GA-CDs) are carbon-based nanoparticles synthesized from gallic acid, typically via hydrothermal or pyrolysis methods. They are being investigated for their biocompatible, antioxidant, anticoagulant, and anticancer properties. In the context of hemodialysis, GA-CDs act as membrane-anchored antioxidants and anticoagulants by activating the Nrf2-HO-1 signaling pathway to clear reactive oxygen species (ROS) and inhibiting the activation of tissue factors on endothelial cells and macrophages. Additionally, GA-CDs have demonstrated cytotoxic and apoptotic effects against colorectal cancer cells (such as HCT-116) by upregulating pro-apoptotic genes like Caspase-3 and Bax.
- Other names
- GA-CDsgallic acid-derived carbon dots
Beyond the preview
Go deeper on gallic acid carbon dots.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gallic acid carbon dots.